Liminatus Pharma (LIMN) Common Equity (2024 - 2026)
Liminatus Pharma (LIMN) posted Common Equity of -$132596.0 for Q1 2026, up 98.65% sequentially from -$9.8 million in Q4 2025, and up 99.33% YoY from -$66522.2 in Q1 2025.
Liminatus Pharma (LIMN) Common Equity (2024 - 2026) Analysis & Trends
Liminatus Pharma has reported Common Equity for 3 years, with the latest figure at -$132596.0 in Q1 2026.
- Quarterly Common Equity rose 99.33% year-over-year to -$132596.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$132596.0 (up 99.33% YoY) and the FY2025 annual result came in at -$9.8 million, up 49.25% from the prior year.
- Common Equity climbed to -$132596.0 in Q1 2026 per LIMN's latest filing, from -$9.8 million in the prior quarter.
- Over five years, Common Equity peaked at -$132596.0 in Q1 2026 and troughed at -$19.7 million in Q1 2025.
- A 3-year average of -$12.1 million and a median of -$14.2 million in 2024 frame the typical range for Common Equity.
- The sharpest annual moves came in 2025 and 2026: Common Equity surged 49.25% in 2025, then jumped 99.33% in 2026.
- Over 3 years, Common Equity stood at -$19.3 million in 2024, then soared by 49.25% to -$9.8 million in 2025, then surged by 98.65% to -$132596.0 in 2026.
- According to Business Quant data, Common Equity over the past three periods registered -$132596.0, -$9.8 million, and -$1.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Liminatus Pharma | 5.46 Mn | 5.46 Mn | - | 300,612.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -132,596.00 |
| Dec 31, 2025 | -9.81 Mn |
| Sep 30, 2025 | -1.65 Mn |
| Jun 30, 2025 | -8.81 Mn |
| Mar 31, 2025 | -19.67 Mn |
| Dec 31, 2024 | -19.34 Mn |
| Sep 30, 2024 | -19.11 Mn |
| Jun 30, 2024 | -18.51 Mn |